+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Heplisav B"

The Vaccine Adjuvants Market by Type of Vaccine Adjuvant, Route of Administration, Target Therapeutic Area and Key Geographies: Industry Trends and Global Forecasts, 2022-2035 - Product Thumbnail Image

The Vaccine Adjuvants Market by Type of Vaccine Adjuvant, Route of Administration, Target Therapeutic Area and Key Geographies: Industry Trends and Global Forecasts, 2022-2035

  • Report
  • May 2022
  • 231 Pages
  • Global
From
United States Human Vaccines Market Size, Share, Top 45 Human Vaccines Brand In-depth Analysis, Emerging Trends, Current Analysis, Growth, Demand, Opportunity, and Forecast 2022 - 2028 - Product Thumbnail Image

United States Human Vaccines Market Size, Share, Top 45 Human Vaccines Brand In-depth Analysis, Emerging Trends, Current Analysis, Growth, Demand, Opportunity, and Forecast 2022 - 2028

  • Report
  • June 2022
  • 215 Pages
  • United States
From
United States Vaccines Market Size, Top 45 Vaccines Brand In-Depth Analysis, Trends, Shares, Insights, and Forecasts to 2027 - Product Thumbnail Image

United States Vaccines Market Size, Top 45 Vaccines Brand In-Depth Analysis, Trends, Shares, Insights, and Forecasts to 2027

  • Report
  • June 2021
  • 195 Pages
  • United States
From
U.S. Hepatitis Vaccines Market - Growth, Demand, Trends, Opportunity, Forecasts (2021 - 2027) - Product Thumbnail Image

U.S. Hepatitis Vaccines Market - Growth, Demand, Trends, Opportunity, Forecasts (2021 - 2027)

  • Report
  • May 2021
  • 70 Pages
  • United States
From
  • 4 Results (Page 1 of 1)
Loading Indicator

Heplisav B is a vaccine developed by Dynavax Technologies Corporation for the prevention of hepatitis B virus (HBV) infection. It is a recombinant vaccine, meaning it is made from a combination of two different HBV proteins. The vaccine is administered in two doses, one month apart, and is approved for use in adults 18 years of age and older. Heplisav B is the first and only two-dose HBV vaccine approved by the US Food and Drug Administration (FDA). Heplisav B is a part of the larger market of vaccines, which are biological preparations that provide active acquired immunity to a particular disease. Vaccines are used to prevent and treat a wide range of infectious diseases, including influenza, measles, and polio. Vaccines are typically administered through injection, but can also be administered orally or nasally. The Heplisav B market includes companies such as Dynavax Technologies Corporation, Merck & Co., GlaxoSmithKline, Sanofi, and Pfizer. These companies are involved in the research, development, manufacturing, and distribution of Heplisav B and other vaccines. Show Less Read more